Artificial intelligence and machine learning platform to drive innovation for rare disease treatments
Guilford, Conn., Mar. 01, 2019 — InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, is pleased to announce that the company was featured in The Guardian newspaper’s Rare Diseases Campaign on Rare Disease Day. This worldwide event has gained momentum since its inception in 2008 with the main objective of raising awareness on the impact of rare diseases that are more often than not misdiagnosed and mistreated.
According to the National Organization for Rare Disorders (NORD), only 5% of rare diseases have an FDA-approved treatment or therapy. Rare diseases are multifaceted in nature with over 9,000 rare and ultra-rare diseases that span several thousand genes, 3,000+ known molecular-target associations, 1,500+ pathways, and thousands of disease pathophysiologies and symptoms. This presents an ideal opportunity to apply artificial intelligence (AI) and machine learning (ML) to uncover therapeutic insights that hone in on the “best-suited” treatment options and the ideal mode of pharmacotherapy (antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities). InveniAI’s platform, AlphaMeldTM, generates testable hypotheses, therapeutic candidates, and insights that can be sorted based on disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies while factoring in medical, scientific, strategic, and commercial considerations.
InveniAI has leveraged its platform for numerous collaborations such as Alexion, Axcella Health, Centrexion, and most recently Kyowa Hakko Kirin, as well as for internal efforts that have resulted in the identification of a rare disease portfolio.
“While the healthcare industry is making strides to find therapies for rare diseases, we believe that our artificial intelligence and machine learning platform can make a significant impact in helping our partners create breakthrough treatments with a high probability of success,” said Krishnan Nandabalan, Ph.D., CEO and President, InveniAI Corporation. “We are honored to be a part of this rare disease campaign and look forward to establishing new partnerships focused on patient solutions for the rare disease community.”, he added.
InveniAI, a wholly owned subsidiary and technology spin-out of BioXcel Corporation, has pioneered the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries. InveniAI is leveraging AI and ML to harness petabytes of disparate data sets to recognize and unlock value. Our domain expertise spans AI-based innovation monitoring to AI-based drug discovery. Our numerous industry collaborations with Big Pharma, Specialty Pharma, and BioPharma, showcase the value of our platform in recognizing complex patterns and associations to complement and amplify human expertise. We continue to collaborate with our industry partners to address cutting-edge problems across the value chain from internal to external innovation and to complement corporate decision making. We are headquartered in Guilford, CT, USA.
The press releases on this website are provided for historical reference purposes only.
Please note that certain information may have changed since the date of release.